Acumen Pharma focused on Alzheimer’s jumps over a third on trading debut (NASDAQ:ABOS)

In its first trading session after an upsized IPO, Acumen Pharmaceuticals (ABOS), a developer of Alzheimer’s disease therapies, opened more than 50% above its IPO price on Thursday…/nRead More